Voltage-Gated Potassium Channel Kv13 Is Highly Expressed in Human Osteosarcoma and Promotes Osteosarcoma Growth

Scientific and Technologial Innovation Programs of of Nanjing Military Region, China [10MA077]Deregulation of voltage-gated potassium channel subunit Kv1.3 has been reported in many tumors. Kv1.3 promotes tumorigenesis by enhancing cell proliferation while suppressing apoptosis. However, the expression and function of Kv1.3 in osteosarcoma are unknown. In the present study, we detected the expression of Kv1.3 in human osteosarcoma cells and tissues by RT-PCR, Western blot and immunohistochemistry. We further examined cell proliferation and apoptosis in osteosarcoma MG-63 cells and xenografts following knockdown of Kv1.3 by short hairpin RNA (shRNA). We found that Kv1.3 was upregulated in human osteosarcoma. Knockdown of Kv1.3 significantly suppressed cell proliferation and increased apoptosis as demonstrated by enhanced cleavage of poly (ADP-ribose) polymerase (PARP) and the activation of Caspase-3/7. Furthermore, adenovirus delivered shRNA targeting Kv1.3 significantly inhibited the growth of MG-63 xenografts. Taken together, our results suggest that Kv1.3 is a novel molecular target for osterosarcoma therapy

Co／SiO_2催化剂上模拟生物质合成气F-T合成的实验研究

比较了工业合成气(A)(H2:CO:N2=64:32:4,vol%)和生物质合成气(B)(H2:CO:CO2:N2=45:45:7:3,vol%)在Co/SiO2催化剂上F-T合成的反应性能.在T=513K,P=2.0MPa,GHSV=1000h-1的条件下,气体(A)和气体(B)的(H2+CO)转化率X(H2+co)和CH4选择性SCH4分别为95.54%、41.24%和17.19%、12.25%.在反应产物的分布上,两种气体的G5+烃选择性SC5+分别为67.46%、80.62%,气体(B)的产物向高碳数烃类迁移.气体(B)100h稳定性实验表明:24h后反应活性和液态烃类选择性基本稳定,XCO和G5+收率平均值分别为29.13%、131.30g·m-3(syngas).与工业合成气相比,生物质合成气液态烃类选择性高

Co/SiO2催化剂上模拟生物质合成气F-T合成的实验研究

比较了工业合成气(A)(H2:CO:N2=64:32:4,vol%)和生物质合成气(B)(H2:CO:CO2:N2=45:45:7:3,vol%)在Co/SiO2催化剂上F-T合成的反应性能.在T=513K,P=2.0MPa,GHSV=1000h-1的条件下,气体(A)和气体(B)的(H2+CO)转化率X(H2+co)和CH4选择性SCH4分别为95.54%、41.24%和17.19%、12.25%.在反应产物的分布上,两种气体的G5+烃选择性SC5+分别为67.46%、80.62%,气体(B)的产物向高碳数烃类迁移.气体(B)100h稳定性实验表明:24h后反应活性和液态烃类选择性基本稳定,XCO和G5+收率平均值分别为29.13%、131.30g·m-3(syngas).与工业合成气相比,生物质合成气液态烃类选择性高

机器人用RV减速器综合性能试验台技术研究与开发

针对RV减速器的各种性能及精度的试验检测,研制了RV减速器综合性能试验台,可完成传动精度、扭转刚度、背隙、启动停止转矩及空载摩擦转矩等项目测试。试验台基于光、机、电等先进测量技术,提出了光栅高频细分、精密装配和误差补偿等专有技术,实现了高达1″的高精度测量和多性能综合测量,并实现了系列化。通过用户使用验证,完全满足工程试验测试需求

Ether a go-go 1 Silencing in Combination with TRAIL Overexpression Has Synergistic Antitumor Effects on Osteosarcoma

Fujian Natural Science Foundation, China [C0710048]Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been utilized for cancer therapy, but the resistance of cancer cells to TRAIL remains an obstacle. Ether a go-go 1 (Eag1) channel is overexpressed in a variety of cancers and implicated in tumor progression. However, the therapeutic potential of Eag1 in osteosarcoma remains elusive. In this study, we generated CRAd5.TRAIL/siEag1 adenoviral vector that permitted simultaneous knockdown of Eag1 and overexpression of TRAIL and investigated its antitumor effects on human osteosarcoma MG-63 cells. Our results showed that CRAd5.TRAIL/siEag1 induced growth arrest and apoptosis of MG-63 cells in a more efficient manner than CRAd5.TRAIL or CRAd5.siEag1, and had no effect on human osteoblastic hFOB1.19 cells. Furthermore, treatment of an osteosarcoma xenograft model with CRAd5.TRAIL/siEag1 resulted in significant tumor regression and cancer cell apoptosis, compared with treatment with CRAd5. TRAIL or CRAd5.siEag1. Taken together, our results demonstrate that CRAd5.TRAIL/siEag1 may represent an effective strategy for osteosarcoma gene therapy due to the synergistic antitumor effects of Eag1 knockdown and TRAIL overexpression

智能WGL-1型采矿中深孔深度倾角测量仪

介绍了智能ＷＧＬ－１型采矿中深孔深度倾角测量仪的测量原理，硬件电路原理及软件设计。ＷＧＬ－１型中深孔深度倾角测量仪解决广在地质构造复杂的地下矿山采矿中深孔凿岩作业深度及倾角用仪器测量的难题，对提高中深孔质邑，增加矿石产量．保障工人安全均有明显效益

智能WGL-1型采矿中深孔深度倾角测量仪

本文介绍的智能ＷＧＬ－１型采矿中深孔深度倾角测量仪在国内首次成功地解决了在地质构造复杂的地下矿山采矿中深孔凿岩作业深度及倾角用仪器测量的难题，对提高中深孔质量，增加矿石产量，保障工人安全均有明显的实际效益

Short Hairpin RNA (shRNA) Ether a go-go 1 (Eag1) Inhibition of Human Osteosarcoma Angiogenesis via VEGF/PI3K/AKT Signaling

Fujian Natural Science Foundation, China [C0710048]Ether a go-go 1 (Eag1) channel is overexpressed in a variety of cancers but the therapeutic potential of Eag1 in osteosarcoma remains elusive. In this study, we constructed an Ad5-Eag1-shRNA vector and evaluated its efficiency for Eag1 knockdown and its effects on osteosarcoma. Our results showed that Ad5-Eag1-shRNA had high interference efficiency of Eag1 expression and suppressed osteosarcoma growth both in vitro and in vivo. To explore the molecular mechanism underlying tumor growth inhibition induced by Eag1 silencing, the intratumoral microvessel density (MVD) was assessed by CD31 staining and the expression of vascular endothelial growth factor (VEGF) was detected by Western blot analysis. We found that Eag1 silencing led to decreased angiogenesis and VEGF expression in the xenograft model of osteosarcoma. Finally, we detected a time-dependent decrease in VEGF expression and considerably reduced phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) activation in osteosarcoma cells treated by Eag1 shRNA. Taken together, our results suggest that Eag1 silencing inhibits tumor growth and angiogenesis in osteosarcoma via the down regulation of VEGF/PI3K/AKT signaling